The stock of Progyny, Inc. (NASDAQ:PGNY) is a huge mover today! The stock increased 9.44% or $2.63 during the last trading session, reaching $30.49. About 2.54M shares traded or 196.77% up from the average. Progyny, Inc. (NASDAQ:PGNY) has 0.00% since December 8, 2018 and is . It has by 0.00% the S&P500.
The move comes after 7 months positive chart setup for the $2.58 billion company. It was reported on Dec, 8 by Barchart.com. We have $33.23 PT which if reached, will make NASDAQ:PGNY worth $232.20 million more.

Progyny, Inc. (NASDAQ:PGNY) Ratings Coverage

Among 4 analysts covering Progyny (NASDAQ:PGNY), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Progyny has $3300 highest and $2600 lowest target. $29.25’s average target is -4.07% below currents $30.49 stock price. Progyny had 4 analyst reports since November 19, 2019 according to SRatingsIntel.

More notable recent Progyny, Inc. (NASDAQ:PGNY) news were published by: Nasdaq.com which released: “BUZZ-U.S. STOCKS ON THE MOVE-Retail stocks, CRISPR Therapeutics, Slack Technologies – Nasdaq” on November 19, 2019, also Globenewswire.com with their article: “Progyny, Inc. Announces Participation in Upcoming Investor Conference[s] – GlobeNewswire” published on November 26, 2019, Nasdaq.com published: “Better Buy: Shopify vs. Veeva Systems – Nasdaq” on November 30, 2019. More interesting news about Progyny, Inc. (NASDAQ:PGNY) were released by: Benzinga.com and their article: “Benzinga’s Top Upgrades, Downgrades For November 19, 2019 – Benzinga” published on November 19, 2019 as well as Nasdaq.com‘s news article titled: “Keep An Eye On DGII, RDNT, PGNY… – Nasdaq” with publication date: November 15, 2019.

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. The company has market cap of $2.58 billion. The Company’s fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. It currently has negative earnings. The firm also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Source link